| scholarly article | Q13442814 |
| P50 | author | Yukimi Otsuka | Q88471666 |
| P2093 | author name string | Takahiko Horiuchi | |
| Hiroaki Niiro | |||
| Koichi Akashi | |||
| Chikako Kiyohara | |||
| Hiroki Mitoma | |||
| Takuya Sawabe | |||
| Yasutaka Kimoto | |||
| Yojiro Arinobu | |||
| Shuji Nagano | |||
| Mitsuteru Akahoshi | |||
| Masahiro Ayano | |||
| Yusuke Kashiwado | |||
| P2860 | cites work | Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis | Q81412936 |
| Cardiovascular death in rheumatoid arthritis: a population-based study | Q81484761 | ||
| Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab | Q82079424 | ||
| Tumor necrosis factor α inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis | Q85720945 | ||
| Cardiovascular risk and inflammation in rheumatic diseases | Q88840125 | ||
| Improved insulin sensitivity by anti-TNFalpha antibody treatment in patients with rheumatic diseases | Q42845010 | ||
| No association between TNF inhibitor and methotrexate therapy versus methotrexate in changes in hemoglobin A1C and fasting glucose among psoriasis, psoriatic arthritis, and rheumatoid arthritis patients | Q43607813 | ||
| Interleukin-6-deficient mice develop mature-onset obesity | Q43851625 | ||
| Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice | Q44631827 | ||
| Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US* | Q45163891 | ||
| Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis-results from the IDEA study | Q48508157 | ||
| NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. | Q50920620 | ||
| Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. | Q51501693 | ||
| Comparison of the Health Assessment Questionnaire (HAQ) and the modified HAQ (MHAQ) in patients with rheumatoid arthritis. | Q53270415 | ||
| Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. | Q54176069 | ||
| Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth | Q70549000 | ||
| American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis: comment on the article by Felson et al | Q71016863 | ||
| Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis | Q79610823 | ||
| Longterm anti-tumor necrosis factor-alpha treatment in patients with refractory rheumatoid arthritis: relationship between insulin resistance and disease activity | Q80660702 | ||
| Interleukin-6 regulates pancreatic alpha-cell mass expansion | Q24336156 | ||
| Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases | Q28744267 | ||
| Type 2 diabetes as an inflammatory disease | Q29617184 | ||
| C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus | Q29619398 | ||
| Report of the committee on the classification and diagnostic criteria of diabetes mellitus | Q33609765 | ||
| Increase of hemoglobin levels by anti-IL-6 receptor antibody (tocilizumab) in rheumatoid arthritis | Q33689977 | ||
| Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis | Q33910329 | ||
| Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents | Q33915940 | ||
| The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease | Q34237283 | ||
| Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity | Q34238357 | ||
| Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease | Q34444895 | ||
| Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab | Q34658023 | ||
| Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies | Q34889152 | ||
| Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people | Q35004093 | ||
| The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. | Q35092457 | ||
| Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis | Q35257568 | ||
| Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study | Q35352554 | ||
| Spuriously high prevalence of prediabetes diagnosed by HbA(1c) in young indians partly explained by hematological factors and iron deficiency anemia. | Q35841172 | ||
| Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies | Q35863952 | ||
| The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis | Q35864053 | ||
| Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis pat | Q35954667 | ||
| Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study | Q37105174 | ||
| Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms | Q37371379 | ||
| Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. | Q37583248 | ||
| Targeting gp130 to prevent inflammation and promote insulin action. | Q38134113 | ||
| Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study | Q38937245 | ||
| An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy | Q39110166 | ||
| Inflammation and type 2 diabetes: results from KORA Augsburg | Q40403823 | ||
| Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists | Q40561067 | ||
| Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study | Q40603438 | ||
| Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis | Q41951968 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| glycosylation | Q898365 | ||
| glycated hemoglobin | Q311213 | ||
| tocilizumab | Q425154 | ||
| P304 | page(s) | e0196368 | |
| P577 | publication date | 2018-04-25 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study | |
| P478 | volume | 13 |
| Q101239685 | Au-Hemoglobin Loaded Platelet Alleviating Tumor Hypoxia and Enhancing the Radiotherapy Effect with Low-Dose X-ray |
| Q104691836 | C-reactive protein and implications in rheumatoid arthritis and associated comorbidities |
| Q94594246 | COVID-19 and diabetes mellitus: An unholy interaction of two pandemics |
| Q96586586 | Dissecting the Interaction between Coronavirus Disease 2019 and Diabetes Mellitus |
| Q92278035 | IL-17 May Be a Key Cytokine Linking Psoriasis and Hyperglycemia |
| Q99240931 | Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis |
| Q96110131 | Incident diabetes associated with hydroxychloroquine, methotrexate, biologics and glucocorticoids in rheumatoid arthritis: A systematic review and meta-analysis |
| Q99246585 | Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials |
| Q100955273 | Meta-analysis investigating the role of interleukin-6 mediated inflammation in type 2 diabetes |
| Q93272085 | Metabolic Targets for Treatment of Autoimmune Diseases |
| Q96019963 | Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy |
| Q102376007 | Predictors of HbA1c among Adipocytokine Biomarkers in African-American Men with Varied Glucose Tolerance |
| Q112700177 | Regulating Acidosis and Relieving Hypoxia by Platelet Membrane-Coated Nanoparticle for Enhancing Tumor Chemotherapy |
| Q95643265 | Remodeling adipose tissue inflammasome for type 2 diabetes mellitus treatment: Current perspective and translational strategies |
| Q92250159 | Role of Interleukin 6 Inhibitors in the Management of Rheumatoid Arthritis |
| Q92126686 | The role of interleukin-6 in glucose homeostasis and lipid metabolism |
| Q92106320 | Type 2 Diabetes: How Much of an Autoimmune Disease? |
| Q98179275 | Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis |
| Q99352059 | Use of biologic or targeted-synthetic disease-modifying anti-rheumatic drugs and risk of diabetes treatment intensification in patients with rheumatoid arthritis and diabetes mellitus |
| Q92400863 | Useful message in choosing optimal biological agents for patients with autoimmune arthritis |
Search more.